Sernova Corp T.SVA

Incompetence arrives on The Most Inopportune Day

[steadfast]

I can't believe SVA issue the Globe & Mail article as a NR today.
Stock opens $2.21 and Target $2.50 once again knocks the wind out of the sails.

We had such an opportunity to get the stock towards $3.00 and blew it.
Common Sense should tell Dr Loe not  to recommend SVA to The Globe & Mail
until after the Interim Clinical Trial Results are released.
He should have arranged to have it coincide with the following day after results.
It is so easy to be organized if one uses common sense.
To-day's Timing could not be worse.
Dr Loe owes SVA Big Time.  I am grateful we are his Top Pick, but get a new target.

[BioTeck]

Oh boo hoo. Get over it. Like that circus clown could affect the price if it is warranted. Deal will drive the price, not Douggie. Come on Spillup, don't let us down, I even capitalized the S in your name.

[Mercuryfilling1]

Two things, SF.  He’s not a doctor, he’s a Doug (but forgive me, maybe that’s your attempt at humour?)…and SVA didn’t put out a NR about Dougie’s call, the Globe & Mail did that. Also, lots of investors here took this week’s surge as an opportunity to pare back (5% in my case) just in case Monday isn’t the “come to Jesus” moment we’ve all been waiting for. I hope it is, but based on

[Mercuryfilling1]

...I'll have to retract his not being a "doctor". I see now that he has a PhD, just like some of the taxi drivers in my town.

[rixpix]

I agree with you, Merc. Nothing wrong with taking a bit off the table here. No one ever went broke selling at a profit.   Also agree with BioTeck that it's not the articles and price targets that'll dictate what price SVA will be. WIthout great results or any deals coming soon, price targets won't matter. Agree with Red Barron too. The analyst's price target will, no doubt